trial

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCTId NCT07459660
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 210 (estimated)
Sponsored by MapLight Therapeutics
Primary completion 2029-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
210 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-03-25
Primary completion
2029-03
Eligibility
ALL · 55 Years · 91 Years

Interventions & indications

Drugs
ML-007C-MA

Sponsors

MapLight TherapeuticsLead Sponsor

Investigators

1
MapLight TherapeuticsStudy Director

Sites

3 total
Doral, United StatesMiami, United StatesMiami, United States

Linked catalysts

1
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — primary completion2029-03

Facts & assertions

4 sourced
Enrollment
210
Phase
PHASE2
Primary Completion Date
2029-03
Status
RECRUITING
relationships
The graph out of here
drug
ML-007C-MA
drug
lead_sponsor
MapLight Therapeutics
company
indication
Hallucinations
indication
Dementia
indication
Tauopathies
indication
investigator
MapLight Therapeutics
person